SS 09 - Head and Neck 1: Highest-Rated Abstracts for Virally-Mediated Head and Neck Cancer

Presentations

• 04:45pm - 06:00pm PT

  Head and Neck 1: Highest-Rated Abstracts for Virally-Mediated Head and Neck Cancer

  Speaker: Anna Lee, MD, MPH - University of Texas MD Anderson Cancer Center, Houston
• 04:45pm - 04:55pm PT

  Integration of Circulating Tumor HPV-DNA with PET/CT for Improved Surveillance of HPV-Associated Oropharyngeal Cancer: A Secondary Analysis of a Prospective Trial

  Speaker: Abed Rahman Kawakibi, MD - Department of Radiation and Cellular Oncology, University of Chicago, Chicago
• 04:55pm - 05:05pm PT

  HPV ctDNA Kinetics during Radiation and in Surveillance in a Phase II De-Escalation Trial for Early-Stage p16+ Oropharynx Cancer

  Speaker: Luke Higgins, MD - University of Michigan, Ann Arbor
• 05:05pm - 05:15pm PT

  The Influence of Chemo-Radiotherapy Dose and Radiotherapy Volumes on Peripheral Immunity in HPV+ Oropharyngeal Cancer

  Speaker: Nadeem Riaz, MD, MS - memorial sloan kettering, new york
• 05:15pm - 05:25pm PT

  A Phase IV Evaluation of De-Escalated Adjuvant Radiation Therapy (DART) as a Standard of Care in Human Papillomavirus Associated Oropharyngeal Squamous Cell Carcinoma

  Speaker: Cecelia Hidalgo, BA - Mayo Clinic, Rochester
• 05:25pm - 05:35pm PT

  Long-Term Outcomes Following Substantial De-Escalation of Elective Radiotherapy Dose and Volume in Patients Treated with Definitive Chemoradiotherapy for HPV-Associated Oropharyngeal Cancer

  Speaker: Amir Safavi, MD, MSc - Memorial Sloan Kettering Cancer Center, New York
• 05:35pm - 05:45pm PT

  A Multi-Site Single-Arm Phase I/II Trial of Selective Avoidance of Nodal VolumEs at Minimal Risk (SAVER) in the Contralateral N0 Neck of Patients with p16-Positive Oropharynx Cancer

  Speaker: Jason Molitoris, MD, PhD - University of Maryland School of Medicine, Baltimore
• 05:45pm - 05:55pm PT

  Discussant

  Speaker: John Lukens, MD - University of Pennsylvania Health System, Philadelphia